


PHARMACEUTICAL 2017

Orgenesis Inc. Rank 115 of 313







PHARMACEUTICAL 2017

Orgenesis Inc. Rank 115 of 313



The relative strengths and weaknesses of Orgenesis Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Orgenesis Inc. compared to the market average is the variable Intangible Assets, increasing the Economic Capital Ratio by 190% points. The greatest weakness of Orgenesis Inc. is the variable Cost of Goods Sold, reducing the Economic Capital Ratio by 102% points.

The company's Economic Capital Ratio, given in the ranking table, is -91%, being 326% points above the market average of -417%.

Input Variable	Value in 1000 USD
Assets, Current	4,205
Cost of Goods Sold	7,657
Intangible Assets	24,634
Liabilities, Current	14,576
Liabilities, Non-Current	8,333
Other Assets	75
Other Compr. Net Income	81
Other Expenses	73
Other Liabilities	0
Other Net Income	536
Property and Equipment	4,573
Research and Development	2,157
Revenues	6,397
Selling, General and Administrative Expense	6,240

Output Variable	Value in 1000 USD
Assets	33,487
Liabilities	22,909
Expenses	16,127
Stockholders Equity	10,578
Net Income	-9,194
Comprehensive Net Income	-9,154
Economic Capital Ratio	-91%